ClinicalTrials.gg
RecruitingNCT06977724Updated Aug 10, 2026

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

A Phase 1 interventional study of ABBV-319 in Dry Eye Syndrome and Systemic Lupus Erythematosus, sponsored by AbbVie. Recruiting at 11 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Dry Eye Syndromes by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · AbbVie.

Planned enrollment
34th of 40
36 · median 80
Started
2025
with 1 other
Phase 1
3 of 48
1 open now
Registered
47th of 48
by date

Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 34th largest by planned enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 47th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 48 studies in Dry Eye Syndromes by AbbVie is open now, in 3 countries.

By country, each count listing its studies:

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Dry Eye Syndromes by AbbVie, or all of them as a file.
02

Study summary

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Sjorgren's disease (SjD) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement and Rheumatoid arthritis (RA) is a long-lasting autoimmune disease that causes the body's immune system to attack itself. RA targets the body's joints, causing inflammation (swelling, pain, and redness). ABBV-319 exhibits potential B cell depletion in SLE, SjD and RA which are characterized by B cell hyperactivity. The purpose of this study is to assess the pharmacokinetics, safety, and efficacy of ABBV-319 in adult participants with SLE, SjD and RA.

ABBV-319 is an investigational drug being developed for the treatment of SLE , SjD and RA. Participants are placed in 1 of 8 groups called treatment arms. Each group receives a different dose of ABBV-319 depending on whether they have SLE, SjD or RA. Around 48 adult participants with SLE, SjD or RA will be enrolled at approximately up to 17 sites worldwide.

Participants will receive 2 doses of IV ABBV-319 21 days apart and will be followed for up to 343 days.

There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Dry Eye Syndrome
  • Systemic Lupus Erythematosus

Keywords

  • Dry Eye Syndrome
  • Systemic Lupus Erythematosus
  • ABBV-319
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Systemic Lupus Erythematosus (SLE) Population - Clinical diagnosis of SLE at least 6 months prior to Screening as defined by the 2019 European Alliance of Associations for Rheumatology (EULAR)/American College Of Rheumatology (ACR) classification criteria for SLE and a positive antinuclear antibody (ANA) >= 1:80 drawn at Screening.
  • SLE Population - Anti-double stranded DNA (dsDNA), anti-Smith (Sm), anti-ribonucleoprotein (RNP), or anti-Sjogren's syndrome Ag A (SSA) Abs above the (ULN).
  • Sjogren's Disease (SjD) Population - Primary diagnosis of SjD at least 6 months prior to Screening as defined by the ACR/EULAR 2016 Criteria.
  • SjD Population - EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) >= 5 at Screening.
  • SjD Population - EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) >= 5 at Screening.
  • Rheumatoid Arthritis (RA) Population - Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA.
  • RA Population - Rheumatoid Factor (RF) or ACPA above the ULN at Screening.
  • RA Population - Confirmation of at least moderate disease activity at Screening, defined by both of the following disease activity criteria:

    • Presence of at least 6 swollen and 6 tender joints at Screening using the 68 (tender)/66 (swollen) joint count.
    • hs-CRP ≥3 mg/L.

Exclusion criteria

Exclusion Criteria:

  • History of infection as defined in the protocol.
  • Any of the medical diseases or disorders listed in the protocol.
  • History of (per investigator's judgment) drug or alcohol abuse within the 6 months prior to Screening.
  • Any planned elective surgery that would impact study procedures or assessments through the completion of the Day 365 assessments.
  • Any clinically significant abnormalities at Screening.
  • RA-Specific Exclusion Criteria - History of RA overlap syndromes, including but not limited to, SLE, SjD, scleroderma, mixed connective tissue disease, or polymyositis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    ABBV-319 Group 1: SLE Participants

    Systemic Lupus Erythematosus (SLE) participants will receive 2 doses of ABBV-319 Dose A 21 days apart.

    Drug: ABBV-319

  • Experimental
    ABBV-319 Group 2: SLE Participants

    SLE participants will receive 2 doses of ABBV-319 Dose B 21 days apart.

    Drug: ABBV-319

  • Experimental
    ABBV-319 Group 3: SLE Participants

    SLE participants will receive 2 doses of ABBV-319 Dose C 21 days apart.

    Drug: ABBV-319

  • Experimental
    ABBV-319 Group 4: SLE Participants

    SLE participants will receive 2 doses of ABBV-319 Dose D 21 days apart.

    Drug: ABBV-319

  • Experimental
    ABBV-319 Group 5: SjD Participants

    Sjogren's disease (SjD) participants will receive 2 doses of ABBV-319 Dose TBD 21 days apart.

    Drug: ABBV-319

  • Experimental
    ABBV-319 Group 6: SjD Participants

    SjD participants will receive 2 doses of ABBV-319 Dose TBD 21 days apart.

    Drug: ABBV-319

  • Experimental
    ABBV-319 Group 7: RA Participants

    Rheumatoid Arthritis (RA) participants will receive 2 doses of ABBV-319 Dose TBD 21 days apart.

    Drug: ABBV-319

  • Experimental
    ABBV-319 Group 8: RA Participants

    RA participants will receive 2 doses of ABBV-319 Dose TBD 21 days apart.

    Drug: ABBV-319

Interventions

  • DrugABBV-319

    Intravenous (IV) Infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 400 days

  2. Change from Baseline in B Cells in Blood and Tissue

    Change from baseline in B cells in blood and tissue.

    Time frame: Up to approximately 400 days

  3. Maximum Plasma Concentration (Cmax) of ABBV-319

    Cmax of ABBV-319.

    Time frame: Up to approximately 400 days

  4. Time to Cmax (Tmax) of ABBV-319

    Tmax of ABBV-319.

    Time frame: Up to approximately 400 days

  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-319

    t1/2 of ABBV-319.

    Time frame: Up to approximately 400 days

  6. Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUCt) of ABBV-319

    AUCt of ABBV-319.

    Time frame: Up to approximately 400 days

  7. Percentage of Participants with Detection of Anti-Drug Antibodies (ADAs) for ABBV-319

    Percentage of participants with detection of ADAs for ABBV-319.

    Time frame: Up to approximately 400 days

  8. Percentage of Participants with Detection of Neutralizing Antibodies (nAbs) for ABBV-319

    Percentage of participants with detection of nAbs for ABBV-319.

    Time frame: Up to approximately 400 days

07

Study locations

9 of 11 sites recruiting
  • Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 278239
    Avon Park, Florida 33825, United States
    Not yet recruiting
  • Clinical Research Of West Florida - Phase I Unit /ID# 275834
    Clearwater, Florida 33765, United States
    Not yet recruiting
  • Life Clinical Trials - Colonial Drive - Margate /ID# 276050
    Margate, Florida 33063, United States
    Recruiting
  • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 275836
    Tampa, Florida 33606, United States
    Recruiting
  • Advanced Quality Medical Research /ID# 278462
    Orland Park, Illinois 60462, United States
    Recruiting
  • Private Practice - Dr. Ramesh C. Gupta /ID# 275826
    Memphis, Tennessee 38119, United States
    Recruiting
    • Site Coordinator · Contact901-681-9670
  • Integrative Rheumatology of South Texas - Harlingen /ID# 276458
    Harlingen, Texas 78550, United States
    Recruiting
    • Site Coordinator · Contact956-423-1112
  • Les Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre /ID# 272692
    Strasbourg, Alsace 67200, France
    Recruiting
  • CHU de Montpellier - Hopital Lapeyronie /ID# 279892
    Montpellier, Herault 34090, France
    Recruiting
  • Amsterdam University Medical Center /ID# 274286
    Amsterdam, North Holland 1105 AZ, Netherlands
    Recruiting
  • Universitair Medisch Centrum Utrecht /ID# 273398
    Utrecht, 3584 CX, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2029, 43 months after the start.

Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
May 18, 2025
StartActual
Aug 26, 2025
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06977724
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 18, 2025
Start date
Aug 26, 2025
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Aug 10, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion